Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?

Competing Interests: Conflicts of interest: A.H. and C.Z. have no disclosures. R.P.G. declares the following: Institutional research grant to the TIMI Study Group at Brigham and Women’s Hospital from Anthos and Daiichi Sankyo; Honoraria for Lecture/CME programmes from Daiichi Sankyo, Medical Education Resources, Menarini, Merck, Pfizer, SAJA, Servier, Shanghai Medical Telescope; Consultant fees from AstraZeneca, CryoLife, Daiichi Sankyo, Hengrui, Janssen, Pfizer, and Samsung. R.P.G. is a member of the TIMI Study Group which has received institutional research grant support through Brigham and Women’s Hospital from AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Merck, Novartis, Pfizer, The Medicines Company. R.D.C. reports grants from Boehringer Ingelheim, Bayer, BMS/Pfizer Alliance, Daiichi Sankyo, Menarini, Roche, Novartis, Sanofi, Merck, Portola, AstraZeneca, Amgen and Guidotti, all outside the submitted work.